Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments Source: Eur Respir Rev, 31 (163) 210212; 10.1183/16000617.0212-2021 Year: 2022
Paradoxical response during antibiotic treatment in patients with Mycobacterium avium complex lung disease Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020
Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2005; 26: 1092-1096 Year: 2005
Combined chemotherapy in Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 657s Year: 2005
Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype Source: Eur Respir J, 50 (3) 1602503; 10.1183/13993003.02503-2016 Year: 2017
Association between injectable aminoglycoside treatment duration and outcomes in cavitary Mycobacterium avium complex lung disease Source: International Congress 2018 – Challenges in treating tuberculosis and nontuberculous mycobacteria Year: 2018
Factors related to response to intermittent treatment of mycobacterium avium complex lung disease Source: Eur Respir J 2006; 28: Suppl. 50, 557s Year: 2006
Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease Source: Eur Respir J, 54 (1) 1900118; 10.1183/13993003.00118-2019 Year: 2019
Hospital-based antibiotic use in patients with Mycobacterium avium complex Source: ERJ Open Res, 4 (4) 00109-2018; 10.1183/23120541.00109-2018 Year: 2018
Susceptibility to nontuberculous mycobacterial lung disease Source: Eur Respir J 2008; 31: 1322-1333 Year: 2008
Clinical relevance of differentiation between Mycobacterium avium and M. intracellulare in M. avium complex pulmonary disease in Croatia Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019
Isolation of M. abscessus from patients with M. avium complex (MAC) lung disease Source: Annual Congress 2013 –Bacterial, fungal and mycobacterial infections Year: 2013
Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course Source: Eur Respir J , 49 (3) 1600537; DOI: 10.1183/13993003.00537-2016 Year: 2017
The effect of combined chemotherapy according to the guidelines on the treatment for Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 546s Year: 2002
The second recurrence of Mycobacterium avium complex lung disease after successful treatment for first recurrence Source: Eur Respir J, 53 (1) 1801038; 10.1183/13993003.01038-2018 Year: 2019
Mycobacterium avium complex infection: phenotypes and outcomesSource: Eur Respir J, 50 (3) 1701380; 10.1183/13993003.01380-2017 Year: 2017
Is delamanid a potential agent in the treatment of diseases caused by Mycobacterium avium-intracellulare? Source: Eur Respir J 2016; 48: 1803-1804 Year: 2016
Long-term observation of pulmonary Mycobacterium avium complex disease treated with chemotherapy following the guidelines for treatment Source: Annual Congress 2009 - Extrapulmonary tuberculosis and non-tuberculous-mycobacteria (NTM) infections Year: 2009
Clinical analysis of pulmonary Mycobacterium avium complex disease in Japan Source: Annual Congress 2012 - Non-tuberculous and tuberculous mycobacterial infections: from epidemiology to clinical findings Year: 2012
Serodiagnosis of Mycobacterium avium complex pulmonary disease in the USA Source: Eur Respir J 2013; 42: 454-460 Year: 2013